Skip to main content
JIN YANG PHARMACEUTICAL. CO., LTD logo

JIN YANG PHARMACEUTICAL. CO., LTD — Investor Relations & Filings

Ticker · 007370 ISIN · KR7007370000 KO Manufacturing
Open in API
Filings indexed 210 across all filing types
Latest filing 2024-04-09 Transaction in Own Shar…
Country KR South Korea
Listing KO 007370

About JIN YANG PHARMACEUTICAL. CO., LTD

https://www.jinyangpharm.com/

JIN YANG PHARMACEUTICAL. CO., LTD. is a company engaged in the research, development, manufacturing, and sale of pharmaceutical products, with a primary focus on prescription drugs. The company operates a fully automated, high-tech manufacturing facility. Its research and development efforts are dedicated to creating advanced preventive and therapeutic treatments for various diseases. Key areas of R&D include the development of anticancer drugs through molecular biology research, particularly for leukemia, and therapies for metabolic disorders such as diabetes and obesity. The company also develops antivirals and explores formulations based on herbal preparations.

Recent filings

Filing Released Lang Actions
[연장결정]주요사항보고서(자기주식취득신탁계약체결결정)
Transaction in Own Shares Classification · 100% confidence The document is a formal regulatory filing ('주요사항보고서') from Jinyang Pharmaceutical regarding the extension of a trust agreement for the acquisition of its own shares (share buyback). It details the contract period, financial limits, and board resolution dates. Since this document reports the company's decision to engage in a share repurchase/buyback program, it falls under the 'Transaction in Own Shares' category.
2024-04-09 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (AGM) for JinYang Pharmaceutical. It details the approval of financial statements, dividend declarations, appointment of auditors, and changes to business objectives. This falls directly under the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), as it provides the official outcome of shareholder votes at the meeting.
2024-03-21 Korean
[기재정정]사업보고서 (2023.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for Jinyang Pharmaceutical Co., Ltd. for the fiscal year 2023 (46th period). It contains comprehensive financial data, management discussion, business overview, and corporate governance information. This document is the official annual filing required by the Financial Supervisory Service in South Korea, which corresponds to the 10-K filing category in the provided schema. FY 2023
2024-03-21 Korean
[기재정정]주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Correction Report' (정정신고) regarding a 'Notice of Convocation of General Meeting of Shareholders' (주주총회소집공고). It provides updated financial statements (Balance Sheet, Income Statement, Statement of Changes in Equity, Cash Flow Statement) as part of the management's reference materials for the upcoming AGM. Since this document is specifically providing updated financial materials for an AGM, it falls under the AGM-R category.
2024-03-14 Korean
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Correction Report' (정정신고) for a 'Proxy Solicitation & Information Statement' (의결권대리행사권유참고서류). It details specific corrections made to financial statements (balance sheet, income statement, etc.) originally submitted on March 4, 2024, in preparation for an upcoming shareholder meeting. Since the primary purpose of the document is to provide information to shareholders to solicit their votes (proxy materials) and it contains the corrected financial data for the meeting, it falls under the Proxy Solicitation & Information Statement category.
2024-03-14 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from Jinyang Pharmaceutical titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of the audit opinion (unqualified/proper), key financial data (assets, liabilities, equity, revenue, profit), and auditor information. While it contains financial data, it is a standard regulatory disclosure form used in the Korean market to announce the receipt and submission of the audit report to the regulator, rather than the full annual report document itself. Therefore, it fits the 'Audit Report / Information' (AR) category as it provides the audit results and financial summary. FY 2023
2024-03-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.